ADA status in the overall population
| ADA status, n (%) . | Overall population (N = 62) . |
|---|---|
| Negative | 49 (79) |
| Positive | 13 (21) |
| Treatment induced∗ | 12 (92.3) |
| Persistent | 7 (58.3) |
| Transient | 5 (41.7) |
| Treatment enhanced† | 1 (7.7) |
| ADA status, n (%) . | Overall population (N = 62) . |
|---|---|
| Negative | 49 (79) |
| Positive | 13 (21) |
| Treatment induced∗ | 12 (92.3) |
| Persistent | 7 (58.3) |
| Transient | 5 (41.7) |
| Treatment enhanced† | 1 (7.7) |
Patients were considered treatment induced if they were ADA negative or missing data at baseline and developed an ADA response following study drug administration.
Patients were considered treatment enhanced if they were ADA positive at baseline and the titer of one or more samples after baseline were greater than the titer of the baseline sample by a scientifically reasonable margin such as at least 4-fold. ADA, anti-drug antibody.